Ceftriaxone-associated biliary pseudolithiasis in children

Basit Öğe Kaydı
dc.contributor.authorBiner, B
dc.contributor.authorÖner, N
dc.contributor.authorÇeltik, C
dc.contributor.authorBostancioglu, M
dc.contributor.authorTunçbilek, N
dc.contributor.authorGüzel, A
dc.contributor.authorKarasalihoglu, S
dc.date.accessioned2024-06-12T10:55:59Z
dc.date.available2024-06-12T10:55:59Z
dc.date.issued2006
dc.departmentTrakya Üniversitesien_US
dc.description.abstractPurpose. Ceftriaxone is known to induce reversible precipitations, known as pseudolithiasis, in the gallbladder and urinary tract. The aim of this study was to investigate the incidence and predisposing factors that contribute to this side effect. Methods. A prospective study was conducted in 156 children admitted for the treatment of various infections with different daily ceftriaxone doses (50 mg/kg, 75 mg/kg, and 100 mg/kg). Sonographic examinations of the gallbladder and urinary tract were performed before treatment on the third and seventh day of therapy, and at the first and second month after the end of treatment. Patients with positive findings were followed with weekly sonographic examinations until the abnormality resolved. Results. Abnormal gallbladder sonograms were demonstrated in 27 children (17%); 16 of them (10%) had gallbladder lithiasis, 11 had gallbladder sludge (7%) (n = 4 on the third day, n = 23 on the seventh day), and 1 developed urolithiasis (0.6%). Five children (19%) were symptomatic. The abnormalities resolved after a mean of 16 days (range 10-30 days). Patients with pseudolithiasis were older and treated with higher drug doses than those with normal sonographic findings (P< 0.01 and P< 0.05, respectively). Conclusions. Biliary pseudolithiasis (and infrequently nephrolithiasis) usually occurs in children receiving high doses of ceftriaxone. It is generally asymptomatic. When this reversible complication becomes symptomatic, unnecessary cholecystectomy should be avoided. (C) 2006 Wiley Periodicals, Inc.en_US
dc.identifier.doi10.1002/jcu.20228
dc.identifier.endpage222en_US
dc.identifier.issn0091-2751
dc.identifier.issue5en_US
dc.identifier.pmid16673364en_US
dc.identifier.scopus2-s2.0-33745011072en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage217en_US
dc.identifier.urihttps://doi.org/10.1002/jcu.20228
dc.identifier.urihttps://hdl.handle.net/20.500.14551/19626
dc.identifier.volume34en_US
dc.identifier.wosWOS:000238102100002en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherJohn Wiley & Sons Incen_US
dc.relation.ispartofJournal Of Clinical Ultrasounden_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectCeftriaxoneen_US
dc.subjectBiliary Pseudolithiasisen_US
dc.subjectNephrolithiasisen_US
dc.subjectUltrasonographyen_US
dc.subjectPediatricsen_US
dc.subjectTherapyen_US
dc.subjectNephrolithiasisen_US
dc.subjectCholelithiasisen_US
dc.subjectSludgeen_US
dc.titleCeftriaxone-associated biliary pseudolithiasis in childrenen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu